- Home
- TKNO vs RIGL Comparison
TKNO vs RIGL Comparison
Compare TKNO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- RIGL
- Stock Information
- Founded
- TKNO 1996
- RIGL 1996
- Country
- TKNO United States
- RIGL United States
- Employees
- TKNO N/A
- RIGL N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- RIGL Health Care
- Exchange
- TKNO Nasdaq
- RIGL Nasdaq
- Market Cap
- TKNO 256.9M
- RIGL 335.5M
- IPO Year
- TKNO 2021
- RIGL 2000
- Fundamental
- Price
- TKNO $4.35
- RIGL $38.85
- Analyst Decision
- TKNO
- RIGL Buy
- Analyst Count
- TKNO 0
- RIGL 5
- Target Price
- TKNO N/A
- RIGL $38.20
- AVG Volume (30 Days)
- TKNO 224.0K
- RIGL 995.6K
- Earning Date
- TKNO 08-07-2025
- RIGL 08-05-2025
- Dividend Yield
- TKNO N/A
- RIGL N/A
- EPS Growth
- TKNO N/A
- RIGL N/A
- EPS
- TKNO N/A
- RIGL 5.43
- Revenue
- TKNO $38,923,000.00
- RIGL $267,921,000.00
- Revenue This Year
- TKNO $9.52
- RIGL $59.93
- Revenue Next Year
- TKNO $15.20
- RIGL N/A
- P/E Ratio
- TKNO N/A
- RIGL $7.15
- Revenue Growth
- TKNO 11.40
- RIGL 105.62
- 52 Week Low
- TKNO $4.00
- RIGL $12.66
- 52 Week High
- TKNO $10.37
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- RIGL 68.57
- Support Level
- TKNO $4.22
- RIGL $39.00
- Resistance Level
- TKNO $4.94
- RIGL $42.08
- Average True Range (ATR)
- TKNO 0.29
- RIGL 2.32
- MACD
- TKNO -0.00
- RIGL -0.37
- Stochastic Oscillator
- TKNO 16.75
- RIGL 53.26
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.